Beijing Gene+ Raises 250 Million Yuan in Series B+
Beijing Gene+, a domestic oncology precision medicine company, announced that it has completed a B+ round of financing with a total amount of more than 250 million yuan. This round of investment was led by Huagai Capital, with new and existing shareholders including Aier Medical, Shengshan Assets, Shengyu Investment, and Honghui Capital. Hanergy Capital served as the financial advisor for this round of financing.
This round of financing will be used to accelerate the compliance of domestic oncology NGS admissions solutions in more hospitals, accelerate the registration and application of large tumor panels, promote the wide application of the T7 platform, and the continuous development of early tumor screening products.
After cultivating the tumor market for five years, Gene+ has formed two domestic NGS and gene big data platforms to support the development of the four major businesses of clinical testing, medical equipment, scientific and technological cooperation, and early tumor screening: in response to the real clinical needs, it has launched high-quality, cost-effective, and The Onco series of tumor clinical genetic testing products, which meet the needs of individualized treatment of cancer patients and cover all cancer types, entire disease courses, and multiple dimensions, have been applied to more than 500 key hospitals across the country, and accumulated more than 180,000 test samples, creating industry information One of the most complete and largest tumor baseline databases.
In 2019, Gene+'s domestically produced sequencers, kits and supporting software were continuously certified, occupying the commanding heights of the IVD track with the advantage of "complete three certificates". Domestic and standardized NGS products and services have been repeatedly evaluated and evaluated by domestic and foreign authoritative organizations such as the National Health Commission Clinical Examination Center (NCCL), the American Association of Pathologists (CAP), the European Molecular Genetic Diagnosis Quality Alliance (EMQN) The proficiency test has been continuously verified, and it has entered the pathology, laboratory and precision medicine centers of more than 20 key hospitals, and is well received by clinical users.
At the same time, Gene+ provides pharmaceutical companies with scientific research and clinical services throughout the entire process of tumor drug development, and T7-based scientific research collaboration sequencing services have also become the company’s fast-growing business line.